Login
Axonics, Inc. logo

Axonics, Inc.

axonics.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 7, 2024. Its latest SEC filing is a 15-12G from Nov 25, 2024.

The sections below describe the company as of the FY2023 annual report.

What Did They Do?

Develops and sells implanted nerve-stimulation systems to treat bladder and bowel dysfunction in adults. Also sells a urethral gel to treat stress urinary incontinence in women.

How Did They Make Money?

Axonics sells products to customers and distributors; sales occur when the goods are handed over, and payment is typically due within three months.

FY2023 revenue by product or service revenue
SegmentShareRevenue
SNM net revenue
80%
FY2020: 100%
Bulkamid net revenue
20%
FY2020: 0.0%

Who Were Their Customers?

Its sales team sells directly to urologists, urogynecologists and colorectal surgeons; distributors serve some international markets.

Did Revenues Turn Into Profits?

No. It lost $6.1M in FY2023.

Operating income, FY2023
−7% of revenue
▲ +60% (Loss) vs FY2022 (−$64.9M, −24%)
Net income, FY2023
−2% of revenue
▲ +90% (Loss) vs FY2022 (−$59.7M, −22%)
Free cash flow, FY2023
−2% of revenue
▼ Turned to a loss vs FY2022 ($968K, 0%)

How Were They Changing?

Since the FY2023 annual report
Latest quarter: Q3 FY2024, the three months to Sep 30, 2024
Revenue
▲ +25%
vs $93.1M in Q3 FY2023
Net income
▼ Turned to a loss
vs $3.9M in Q3 FY2023
SNM net revenue share of revenue vs 79.4% in Q3 FY2023
  • Nov 15, 2024 Merger closed, making Axonics a wholly owned subsidiary The company also requested Nasdaq delisting, and trading was suspended.

Grew. Revenue grew 26.5x in 4 years, from $13.8M in FY2019 to $366.4M in FY2023, about 127% a year.

Broader implanted therapy lineup The older report described a rechargeable implanted nerve-stimulation system and listed a non-rechargeable model as a future product goal. The latest report describes both rechargeable and recharge-free systems.

Revenue over time
SNM net revenue Bulkamid net revenue
$500M$250M$0

Who Did They Compete With?

Competes with Medtronic and Allergan

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support